Eric Toussirot

Summary

Country: France

Publications

  1. ncbi Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Curr Opin Rheumatol 19:340-5. 2007
  2. ncbi Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice
    Eric Toussirot
    Rheumatology Department, Besançon Hospital, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besancon, France
    Joint Bone Spine 77:142-5. 2010
  3. ncbi Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Boulevard Fleming, Besancon Cedex, France
    Arthritis Res Ther 11:R101. 2009
  4. ncbi Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, EA 3186 Agents Pathogènes et Inflammation, IFR 133 University of Franche Comté, CIC Biotherapy 506, St Jacques Hospital, Besancon, France
    J Rheumatol 36:2421-7. 2009
  5. ncbi Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon, Cedex, France
    Metabolism 56:1383-9. 2007
  6. ncbi Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies
    Eric Toussirot
    University Hospital Jean Minjoz Bd Fleming, Department of Rheumatology, F 25030 Besancon, Cedex, France
    Expert Opin Pharmacother 6:35-43. 2005
  7. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an update
    Eric Toussirot
    University Hospital Jean Minjoz, Department of Rheumatology, Besancon Cedex, France
    Expert Opin Pharmacother 8:2089-107. 2007
  8. ncbi Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 27:523-31. 2010
  9. ncbi Elevated adiponectin serum levels in women with systemic autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besancon Cedex, France
    Mediators Inflamm 2010:938408. 2010
  10. ncbi Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon Cedex, France
    Recent Pat Inflamm Allergy Drug Discov 1:39-47. 2007

Detail Information

Publications29

  1. ncbi Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Curr Opin Rheumatol 19:340-5. 2007
    ..Thus, bisphosphonates may be reasonably used as a therapeutic agent in ankylosing spondylitis...
  2. ncbi Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice
    Eric Toussirot
    Rheumatology Department, Besançon Hospital, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besancon, France
    Joint Bone Spine 77:142-5. 2010
    ..To report our experience with rituximab therapy in patients with rheumatoid arthritis (RA) and a history of severe or recurrent bacterial infections...
  3. ncbi Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Boulevard Fleming, Besancon Cedex, France
    Arthritis Res Ther 11:R101. 2009
    ..Here, we evaluated circulating levels of sCTLA-4 as a marker of immune dysregulation in SpA. Intracellular CTLA-4 and levels of CTLA-4 transcript expression in peripheral blood lymphocytes (PBL) were also studied...
  4. ncbi Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, EA 3186 Agents Pathogènes et Inflammation, IFR 133 University of Franche Comté, CIC Biotherapy 506, St Jacques Hospital, Besancon, France
    J Rheumatol 36:2421-7. 2009
    ..To describe cases of development of pulmonary nodulosis or aseptic granulomatous lung disease in patients with rheumatoid arthritis (RA) receiving anti-tumor necrosis factor-alpha (TNF-alpha) therapy...
  5. ncbi Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon, Cedex, France
    Metabolism 56:1383-9. 2007
    ..Leptin production was reduced in contrast with normal levels of adiponectin. These adipokine results, together with high serum ghrelin levels, may influence the inflammatory response in AS...
  6. ncbi Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies
    Eric Toussirot
    University Hospital Jean Minjoz Bd Fleming, Department of Rheumatology, F 25030 Besancon, Cedex, France
    Expert Opin Pharmacother 6:35-43. 2005
    ..Further studies are required to confirm these preliminary data and to better determine the optimal regimen (dosage and rhythm) of administration...
  7. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an update
    Eric Toussirot
    University Hospital Jean Minjoz, Department of Rheumatology, Besancon Cedex, France
    Expert Opin Pharmacother 8:2089-107. 2007
    ....
  8. ncbi Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 27:523-31. 2010
    ..Thus, the clinician must be familiar with the clinical characteristics and particularities of this group of inflammatory rheumatic diseases...
  9. ncbi Elevated adiponectin serum levels in women with systemic autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besancon Cedex, France
    Mediators Inflamm 2010:938408. 2010
    ..However, the precise consequences of these elevated serum adiponectin levels on the metabolic syndrome development and atherosclerotic cardiovascular risk in this patient population still needs to be determined...
  10. ncbi Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon Cedex, France
    Recent Pat Inflamm Allergy Drug Discov 1:39-47. 2007
    ....
  11. ncbi Current therapeutics for spondyloarthritis
    Eric Toussirot
    Department of Rheumatology, University Hospital, 25000 Besancon, France
    Expert Opin Pharmacother 12:2469-77. 2011
    ..International recommendations for the management of AS by the Assessment of Spondyloarthritis (ASAS) group were recently updated and discussed the respective place of each current therapeutic option in AS...
  12. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Cedex, France
    Expert Opin Pharmacother 5:581-94. 2004
    ....
  13. ncbi Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon Cedex, France
    Autoimmunity 39:299-306. 2006
    ..Our results suggest that OM-89 has immunomodulatory properties by inducing changes in PBMC cytokines release suggestive of an induced Tr1 response to OM-89...
  14. ncbi Anti-TNF-alpha therapy in ankylosing spondylitis
    Daniel Wendling
    University Teaching Hospital Minjoz, Department of Rheumatology, Boulevard Fleming, F 25030 Besancon, France
    Expert Opin Pharmacother 5:1497-507. 2004
    ..Despite these concerns, Anti-TNF represents a major therapeutic advancement in the treatment of AS...
  15. ncbi Ankylosing spondylitis and Sweet's syndrome
    Daniel Wendling
    Department of Rheumatology, University of Franche Comte, University Teaching Hospital Minjoz, 25030 Besancon, France
    Clin Rheumatol 27:S27-8. 2008
    ..Skin involvement in AS is dominated by psoriasis-type lesions. The occurrence of Sweet's syndrome is seldom reported in this condition...
  16. ncbi Acute pseudogout after pamidronate infusion
    Daniel Wendling
    Department of Rheumatology, University Teaching Hospital Minjoz, EA 3186, University of Franche Comte, Boulevard Fleming, Besancon, France
    Clin Rheumatol 27:1205-6. 2008
    ..Diagnosis was confirmed by synovial fluid analysis and was associated with hypocalcemia. Only a few cases are reported in the literature. The mechanism of this potential side effect remains speculative...
  17. ncbi Recent progress in ankylosing spondylitis treatment
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon, France
    Expert Opin Pharmacother 4:1-12. 2003
    ....
  18. ncbi Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Inflamm Allergy Drug Targets 9:51-9. 2010
    ..It may therefore be regarded as a relevant outcome variable in clinical trials and for the management of patients with RA in clinical practice...
  19. ncbi Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 22:451-69. 2005
    ....
  20. ncbi Epstein-Barr virus in autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besançon and EA 3186 Agents Pathogènes et Inflammation, University of Franche Comte, Besancon, France
    Best Pract Res Clin Rheumatol 22:883-96. 2008
    ..The influence of new and emergent treatments of these autoimmune diseases (biological therapies) on EBV load and the course of latent EBV infection requires further studies...
  21. ncbi Pedicle stress fracture: an unusual complication of pycnodysostosis
    Paul Ornetti
    Department of Rheumatology, University Teaching Hospital, Franche Comte University, 25030, Besancon, France
    Clin Rheumatol 27:385-7. 2008
    ..The dramatic improvement achieved by calcitonin therapy might be related to osteoclastic dysfunction in pycnodysostosis caused by a deficiency of cathepsin K, a cystein protease involved in bone matrix remodelling...
  22. ncbi The contribution of adipose tissue and adipokines to inflammation in joint diseases
    Eric Toussirot
    Department of Rheumatology, Jean Minjoz University Hospital, Bd Fleming, F 25030 Besancon Cedex, France
    Curr Med Chem 14:1095-100. 2007
    ..Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases...
  23. ncbi Symptomatic treatment of a case of Schnitzler's syndrome with pamidronate
    Daniel Wendling
    Joint Bone Spine 75:507-8. 2008
  24. ncbi Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice
    Daniel Wendling
    Rheumatology Department, Minjoz Teaching Hospital, CHU Minjoz, 25030 Besancon, France
    Joint Bone Spine 72:309-12. 2005
    ..Infliximab is a major breakthrough in the management of rheumatoid arthritis (RA). We evaluated infliximab continuation rates and reasons for discontinuation in patients with RA...
  25. ncbi Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis
    Daniel Wendling
    Joint Bone Spine 75:510-1. 2008
  26. ncbi Aseptic discitis in patients with ankylosing spondylitis: a retrospective study of 14 cases
    Sandrine Langlois
    Service de Rhumatologie, , CHU, Boulevard Fleming, , France
    Joint Bone Spine 72:248-53. 2005
    ..Discitis usually occurs at an advanced stage of AS under the form of an erosive condition related to both mechanical factors and osteoporosis. Inaugural or early discitis can occur, however, as a result of the inflammatory process...
  27. ncbi Imaging study scores for ankylosing spondylitis
    Daniel Wendling
    Rheumatology Department, Jean Minjoz Teaching Hospital, Boulevard Fleming, 25030 Besancon Cedex, France
    Joint Bone Spine 73:655-60. 2006
    ..MRI has proved sensitive to change in patients taking TNF antagonists. An outcome measures in rheumatology clinical trials (OMERACT) task force is working on standardizing MRI scores for the spine and sacroiliac joints...
  28. ncbi Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?
    Daniel Wendling
    J Rheumatol 34:1647-9. 2007
  29. ncbi [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies]
    Daniel Wendling
    Service de Rhumatologie, CHU Jean Minjoz, Besancon
    Presse Med 32:1517-24. 2003
    ....